An 81-year-old Hispanic man was referred to our gastrointestinal medical oncology clinic for recurrent colon adenocarcinoma…determined the presence of 2 rare KRAS mutations, N116H and N116T, at codon 116…He received an additional 11 cycles of maintenance 5-FU, leucovorin, and bevacizumab (16 cycles overall) followed by disease progression prompting transition to 5-FU, leucovorin, and irinotecan (FOLFIRI) with bevacizumab. Unfortunately, the patient experienced protracted grade 3 fatigue with FOLFIRI with a worsening performance status, and opted to discontinue this regimen. Surveillance CT imaging before cycle 1 of FOLFIRI had confirmed further disease progression in the hepatic flexure mass.